Literature DB >> 11847456

The menstrual cycle and susceptibility to coriolis-induced sickness.

B Cheung1, R Heskin, K Hofer, M Gagnon.   

Abstract

Survey studies on motion sickness susceptibility suggest that females tend to report greater severity in illness and higher incidence of vomiting than males. Menstruation is said to be a contributing factor. A recent study suggested that females were least susceptible to seasickness during ovulation in a "round the world" yacht race. Sixteen subjects (18-36 years old) were exposed to Coriolis cross-coupling stimulation in the laboratory. They were tested once during permenstruation (Day 1-5), ovulation (Day 12-15) and premenstruation (Day 24-28), based on a normalized 28-day cycle, in a randomised design. Physiological measurements of motion sickness included forearm and calf cutaneous blood flow. Subjective evaluation of sickness symptoms was based on Graybiel's diagnostic criteria and Golding's rating method. Our results indicated that under controlled laboratory conditions, different phases of the menstrual cycle appear to have no influence on subjective symptoms of motion sickness or on cutaneous blood flow increase in the forearm and calf. The lack of commonality between the types and levels of hormones that are released during motion sickness and those that are involved in different menstrual phases appears to support our findings.

Entities:  

Mesh:

Year:  2001        PMID: 11847456

Source DB:  PubMed          Journal:  J Vestib Res        ISSN: 0957-4271            Impact factor:   2.435


  3 in total

Review 1.  Space motion sickness.

Authors:  James R Lackner; Paul Dizio
Journal:  Exp Brain Res       Date:  2006-10-05       Impact factor: 1.972

2.  Susceptibility to nausea and motion sickness as a function of the menstrual cycle.

Authors:  Robert L Matchock; Max E Levine; Peter J Gianaros; Robert M Stern
Journal:  Womens Health Issues       Date:  2008-05-15

3.  Motion sickness prevalence in school children.

Authors:  Isadora Ferreira Henriques; Dhelfeson Willya Douglas de Oliveira; Fernanda Oliveira-Ferreira; Peterson M O Andrade
Journal:  Eur J Pediatr       Date:  2014-06-04       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.